IKT-906

N/A

Report date: 2026/03/19 16:53:32

Base Information

Drug NameIKT-906
Drug Alias Nameanti-CD3/anti-GD2 bispecific T-cell engager (Icell Kealex)IKT-906GD2-TEA-VV
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Oncolytic virusBiologics > T cell engagers
Mechanisms of ActionDisialoganglioside GD2 modulatorsT cell surface glycoprotein CD3 modulatorsT lymphocytes stimulants +[4] 
TargetsDisialoganglioside GD2T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIcell Kealex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIcell Kealex Therapeutics
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A